Effects of calcipotriol on stratum corneum barrier function, hydration and cell renewal in humans.
Calcipotriol, a vitamin D analogue utilized for psoriasis, has irritation as its most frequent reported adverse event. However, studies on its irritant properties in humans have produced conflicting data. This study evaluates the effect of calcipotriol on stratum corneum barrier function, hydration and cell turnover in healthy volunteers, compared with sodium lauryl sulphate (SLS) as a model irritant. Calcipotriol 0.005% ointment and 1% aqueous SLS solution were applied for 60 min once daily for 2 weeks (5 consecutive days weekly) on untreated and on dansyl-chloride-labelled skin. Irritant responses were documented by visual scoring and by measurement of the transepidermal water loss (TEWL) and stratum corneum hydration (electrical capacitance), until day 18. Stratum corneum turnover time (SCTT) was the time in days between staining (day 0) and the disappearance of dansyl fluorescence. SLS caused more erythema, scaling, and a significant TEWL increase for 18 days. In contrast, calcipotriol induced erythema, and slightly but significantly increased TEWL on day 11 only, as compared with the vehicle control (P < 0.05). SLS, but not calcipotriol, caused skin dryness from day 4 to day 18. The shortest SCTT was obtained at SLS-exposed sites (11.2 +/- 0.7 days: mean +/- SD). Calcipotriol significantly shortened SCTT (16.3 +/- 1.1 days) when compared with its vehicle. Compared with the skin irritation induced by SLS, under these test conditions, calcipotriol is a far weaker irritant on normal human skin. In addition, calcipotriol accelerates stratum corneum turnover to a significantly greater extent than its vehicle.
Effendy
I
I
Department of Dermatology, University of Marburg, Germany.
Kwangsukstith
C
C
Chiappe
M
M
Maibach
H I
HI
D000328:Adult; D002117:Calcitriol / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000633:toxicity; D002455:Cell Division / Q000187:drug effects; D003879:Dermatologic Agents / Q000494:pharmacology* / Q000633:toxicity; D003875:Drug Eruptions / Q000209:etiology; D004817:Epidermis / Q000187:drug effects*; D004890:Erythema / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology; D005260:Female; D005712:Galvanic Skin Response / Q000187:drug effects*; D006801:Humans; D008297:Male; D012967:Sodium Dodecyl Sulfate / Q000494:pharmacology; D014870:Water Loss, Insensible / Q000187:drug effects*
D003879:Dermatologic Agents; C055085:calcipotriene; D012967:Sodium Dodecyl Sulfate; D002117:Calcitriol